Neurotech International (ASX:NTI) has received Orphan Drug Designation from the European Commission for NTI164, its lead drug candidate for Rett Syndrome, a neurodevelopmental disorder, according to a Monday filing with the Australian bourse.
The designation grants market exclusivity, reduced regulatory fees, access to research funding, and protocol assistance, the filing said.
Shares of the firm rose past 3% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。